Author

C. L. Kent

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. J. Wisdom· 2 shared D. G. Kirsch· 2 shared J. E. Himes· 2 shared L. Luo· 2 shared Y. M. Mowery· 2 shared Y. Ma· 2 shared A. L. Lazarides· 1 shared A. Subramanian· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Wisdom

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Enhancing radiotherapy response via intratumoral injection of the TLR9 agonist CpG to stimulate CD8 T cells in an autochthonous mouse model of sarcoma

C. Su, C. L. Kent, M. Pierpoint, W. Floyd, L. Luo, N. T. Williams, Y. Ma, B. Peng, A. L. Lazarides, A. Subramanian, J. E. Himes, V. M. Perez, R. D. Hernansaiz-Ballesteros, K. E. Roche, J. L. Modliszewski, , D. G. Kirsch

This study shows that combining radiotherapy with CpG, a TLR9 agonist, enhances tumor response in a mouse sarcoma model by boosting CD8 T cell activity.

bioRxiv · Jan 3, 2024 · PreprintCancer Biology

A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy

A. J. Wisdom, Y. M. Mowery, C. S. Hong, X. Qin, D. Zhang, J. E. Himes, L. Chen, H. Fradin, E. S. Muise, E. S. Xu, D. J. Carpenter, C. L. Kent, K. S. Smythe, N. Williams, L. Luo, , D. G. Kirsch

The paper compares immune landscapes in transplant and primary tumors after immunotherapy and radiotherapy, finding that transplant tumors respond better due to CD8+ T cell enrichment.

bioRxiv · Mar 11, 2020Cancer Biology